Antibiotic Resistance Market Analysis - Global Industry Size, Share, Trends and Forecast 2022 - 2030
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Antibiotic Resistance
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antibiotic Resistance Market By Disease
1.2.2.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.2.2. Global Antibiotic Resistance Market Revenue Share By Disease in 2017
1.2.2.3. Complicated Urinary Tract Infection (cUTI)
1.2.2.4. Complicated Intra-Abdominal Infections (cIAI)
1.2.2.5. Blood Stream Infections (BSI)
1.2.2.6. Clostridium difficile infections (CDI)
1.2.2.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
1.2.2.8. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
1.2.2.9. Community Acquired Bacterial Pneumonia (CABP)
1.2.2.10. Others
1.2.3. Antibiotic Resistance Market By Pathogen
1.2.3.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Pathogen (2015-2026)
1.2.3.2. Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
1.2.3.3. Pseudomonas aeruginosa (Carbapenem-Resistant)
1.2.3.4. Staphylococcus Aureus (Methicillin-Resistant)
1.2.3.5. E. coli/K. pneumoniae (Carbapenem-Resistant)
1.2.3.6. Streptococcus pneumoniae (Penicillin-Non-Susceptible)
1.2.3.7. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
1.2.3.8. Enterococcus faecium (Vancomycin-Resistant)
1.2.3.9. Haemophilus Influenzae (Ampicillin-Resistant)
1.2.3.10. Others
1.2.4. Antibiotic Resistance Market By Drug Class
1.2.4.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.4.3. Lipoglycopeptides
1.2.4.4. Tetracyclines
1.2.4.5. Cephalosporins
1.2.4.6. Combination therapies
1.2.4.7. Others
1.2.5. Antibiotic Resistance Market by Geography
1.2.5.1. Global Antibiotic Resistance Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antibiotic Resistance Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Lipoglycopeptides Production Date of Global Antibiotic Resistance Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antibiotic Resistance Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Antibiotic Resistance Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antibiotic Resistance Major Manufacturers in 2017
CHAPTER 4. ANTIBIOTIC RESISTANCE MARKET BY DISEASE
4.1. Global Antibiotic Resistance Revenue By Disease
4.2. Complicated Urinary Tract Infection (cUTI)
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Complicated Intra-Abdominal Infections (cIAI)
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Blood Stream Infections (BSI)
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Clostridium difficile infections (CDI)
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.8. Community Acquired Bacterial Pneumonia (CABP)
4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.9. Other
4.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. ANTIBIOTIC RESISTANCE MARKET BY PATHOGEN
5.1. Global Antibiotic Resistance Revenue By Pathogen
5.2. Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Pseudomonas aeruginosa (Carbapenem-Resistant)
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Staphylococcus Aureus (Methicillin-Resistant)
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. E. coli/K. pneumoniae (Carbapenem-Resistant)
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Streptococcus pneumoniae (Penicillin-Non-Susceptible)
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Enterococcus faecium (Vancomycin-Resistant)
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Haemophilus Influenzae (Ampicillin-Resistant)
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.10. Others
5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. ANTIBIOTIC RESISTANCE MARKET BY DRUG CLASS
6.1. Global Antibiotic Resistance Revenue By Drug Class
6.2. Oxazolidinones
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Lipoglycopeptides
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Tetracyclines
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Cephalosporins
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Combination therapies
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Others
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY
7.1. North America Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Antibiotic Resistance Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE ANTIBIOTIC RESISTANCE MARKET BY COUNTRY
8.1. Europe Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET BY COUNTRY
9.1. Asia-Pacific Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY
10.1. Latin America Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET BY COUNTRY
11.1. Middle East Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
CHAPTER 12. AFRICA ANTIBIOTIC RESISTANCE MARKET BY COUNTRY
12.1. Africa Antibiotic Resistance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antibiotic Resistance Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Pathogen, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. TPfizer
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Merck
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Allergan
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. The Medicines Company
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Melinta Therapeutics
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Phage Technologies S.A
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Tetraphase Pharmaceuticals
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Nabriva Therapeutics
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Macrolide Pharmaceuticals
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Nemesis Bioscience
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.11. Westway Health
13.11.1. Company Snapshot
13.11.2. Overview
13.11.3. Financial Overview
13.11.4. Type Portfolio
13.11.5. Key Developments
13.11.6. Strategies
13.12. AmpliPhi Biosciences
13.12.1. Company Snapshot
13.12.2. Overview
13.12.3. Financial Overview
13.12.4. Type Portfolio
13.12.5. Key Developments
13.12.6. Strategies
13.13. BioVersys GmbH
13.13.1. Company Snapshot
13.13.2. Overview
13.13.3. Financial Overview
13.13.4. Type Portfolio
13.13.5. Key Developments
13.13.6. Strategies
13.14. Others
13.14.1. Company Snapshot
13.14.2. Overview
13.14.3. Financial Overview
13.14.4. Type Portfolio
13.14.5. Key Developments
13.14.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
Frequently Asked Questions
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
